390 related articles for article (PubMed ID: 12491054)
1. [Physical and technical quality assurance and radiation protection in transperineal interstitial permanent prostate brachytherapy with 125-iodine seeds].
Kaulich TW; Lamprecht U; Paulsen F; Lorenz J; Maurer U; Loeser W; Bichler KH; Nüsslin F; Bamberg M
Strahlenther Onkol; 2002 Dec; 178(12):667-75. PubMed ID: 12491054
[TBL] [Abstract][Full Text] [Related]
2. [Physical basics and clinical realization of interstitial brachytherapy of the prostate with iodine 125].
Kaulich TW; Lamprecht U; Paulsen F; Kahmann F; Maurer U; Henkel TO; Loeser W; Bichler KH; Nüsslin F; Bamberg M
Strahlenther Onkol; 2002 Oct; 178(10):548-55. PubMed ID: 12386786
[TBL] [Abstract][Full Text] [Related]
3. Radiation exposure after permanent prostate brachytherapy.
Cattani F; Vavassori A; Polo A; Rondi E; Cambria R; Orecchia R; Tosi G
Radiother Oncol; 2006 Apr; 79(1):65-9. PubMed ID: 16564593
[TBL] [Abstract][Full Text] [Related]
4. Assessment of radiation safety instructions to patients based on measured dose rates following prostate brachytherapy.
Dauer LT; Zelefsky MJ; Horan C; Yamada Y; St Germain J
Brachytherapy; 2004; 3(1):1-6. PubMed ID: 15110306
[TBL] [Abstract][Full Text] [Related]
5. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
7. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk.
Crook JM; Potters L; Stock RG; Zelefsky MJ
Brachytherapy; 2005; 4(3):186-94. PubMed ID: 16182218
[TBL] [Abstract][Full Text] [Related]
8. Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy.
Schwartz DJ; Davis BJ; Vetter RJ; Pisansky TM; Herman MG; Wilson TM; LaJoie WN; Oberg AL
Brachytherapy; 2003; 2(2):98-102. PubMed ID: 15062147
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
[TBL] [Abstract][Full Text] [Related]
10. In vivo dosimetry with a linear MOSFET array to evaluate the urethra dose during permanent implant brachytherapy using iodine-125.
Bloemen-van Gurp EJ; Haanstra BK; Murrer LH; van Gils FC; Dekker AL; Mijnheer BJ; Lambin P
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1266-72. PubMed ID: 19665317
[TBL] [Abstract][Full Text] [Related]
11. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
Wust P; von Borczyskowski DW; Henkel T; Rosner C; Graf R; Tilly W; Budach V; Felix R; Kahmann F
Radiother Oncol; 2004 Oct; 73(1):39-48. PubMed ID: 15465144
[TBL] [Abstract][Full Text] [Related]
12. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy.
Heysek RV; Gwede CK; Torres-Roca J; Cantor A; Kelley S; Saini AS; Pow-Sang J
Brachytherapy; 2006; 5(4):244-50. PubMed ID: 17118318
[TBL] [Abstract][Full Text] [Related]
13. [Equipment for rapid and reliable perineal implantation of I-125 seeds in prostatic cancer with reduced radiation exposure].
Bruggmoser G; Nanko N; Hempel M; Heitz R; Wannenmacher M
Strahlenther Onkol; 1987 Sep; 163(9):593-4. PubMed ID: 3660225
[TBL] [Abstract][Full Text] [Related]
14. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
Pickett B; Pouliot J
Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
[TBL] [Abstract][Full Text] [Related]
15. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
[TBL] [Abstract][Full Text] [Related]
16. A study of a pretreatment method to predict the number of I-125 seeds required for prostate brachytherapy.
Al-Qaisieh B; Brearley E; St Clair S; Flynn A
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):304-7. PubMed ID: 16618585
[TBL] [Abstract][Full Text] [Related]
17. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
18. [Physical brachytherapy planning].
Muskalla K
Praxis (Bern 1994); 2001 Sep; 90(36):1532-43. PubMed ID: 11593909
[TBL] [Abstract][Full Text] [Related]
19. Prediction of seed migration after transperineal interstitial prostate brachytherapy with I-125 free seeds.
Sugawara A; Nakashima J; Shigematsu N; Kunieda E; Kubo A
Brachytherapy; 2009; 8(1):52-6. PubMed ID: 19154979
[TBL] [Abstract][Full Text] [Related]
20. [Brachytherapy for prostate cancer: high dose rate or low-dose rate?].
Cosset JM; Haie-Meder C
Cancer Radiother; 2005 Dec; 9(8):610-9. PubMed ID: 16226473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
